Chemistry:Radezolid
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous infusion, oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H23FN6O3 |
| Molar mass | 438.463 g·mol−1 |
| 3D model (JSmol) | |
| |
Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne.[1]
References
- ↑ Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal. http://www.hartfordbusiness.com/article/20160801/PRINTEDITION/307289945/melinta-therapeutics-takes-aim-at-deadly-drug-resistant-bacteria.
Further reading
- "Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics". Bioorg. Med. Chem. Lett. 18 (23): 6175–8. December 2008. doi:10.1016/j.bmcl.2008.10.011. PMID 18947996.
- "Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance". Antimicrob. Agents Chemother. 52 (10): 3550–7. October 2008. doi:10.1128/AAC.01193-07. PMID 18663023.
- "In vitro activities of the Rχ-01 oxazolidinones against hospital and community pathogens". Antimicrob. Agents Chemother. 52 (5): 1653–62. May 2008. doi:10.1128/AAC.01383-07. PMID 18316525.
- "Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable [sic?] alternative to the "click" reaction"". Organic Process Research & Development 14: 152–158. 2009. doi:10.1021/op900252a.
- "Structure-based drug design meets the ribosome". Biochem. Pharmacol. 71 (7): 1016–25. March 2006. doi:10.1016/j.bcp.2005.12.026. PMID 16443192.
- Ohlsen K (November 2009). "Novel antibiotics for the treatment of Staphylococcus aureus". Expert Rev. Clin. Pharmacol. 2 (6): 661–72. doi:10.1586/ecp.09.26. PMID 22112259.
 |  |
